Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether treatment with temozolomide will shrink small cell lung cancer tumors. Temozolomide is an oral chemotherapy drug that is currently used to treat brain cancer and melanoma.

As part of this study, we will be doing additional tests that may help us understand how temozolomide works. First, if there is a tumor sample from a biopsy done in the past, it will be analyzed for an abnormal gene that may be present in lung cancer. Before starting temozolomide, a research blood test will be done to look for the same abnormal gene we are looking for in your tumor sample. Also, before starting temozolomide and every time you have a repeat CT scan, a research blood test will be done to analyze the number of tumor cells in your bloodstream.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer

NCT00022711

Lung Cancer

COMPLETED PHASE2

Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer

NCT00003062

Lung Cancer

COMPLETED PHASE2

Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer

NCT00006877

Lung Cancer

COMPLETED PHASE2

Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

NCT00005037

Lung Cancer

COMPLETED PHASE2

Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection

NCT00588341

Melanoma Skin Cancer Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

75 mg/m2/day Temozolomide

75 mg/m2/day Temozolomide for 21 days (7 days off treatment). 28 day cycles.

Group Type EXPERIMENTAL

Temozolomide

Intervention Type DRUG

Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.

200 mg/m2/day Temozolomide

200 mg/m2/day Temozolomide for 5 days (23 days off treatment). 28 day cycles.

Group Type EXPERIMENTAL

Temozolomide

Intervention Type DRUG

Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Temozolomide

Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.

Intervention Type DRUG

Temozolomide

Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have pathologically confirmed SCLC at MSKCC that has progressed after one or two chemotherapy regimens.
* At least 3 weeks must have elapsed since last chemotherapy or radiation treatment and initiation of study treatment.
* Karnofsky performance status \> or = to 60%.
* Patients must have measurable disease, this can include brain metastases.
* Patients must have normal organ and marrow function as defined below:
* \- leukocytes \> 3,000/mcL
* platelets \> 100,000/mcL
* total bilirubin \< 1.5 mg/dL
* AST(SGOT)/ALT(SGPT) \< 2.5 X institutional upper limit of normal
* Creatinine \< 2.0 mg/dl
* For women of child-bearing potential, negative pregnancy test within 7 days prior to starting temozolomide.
* Men and women of childbearing potential must agree to practice adequate contraception.
* Ability to understand and the willingness to sign a written informed consent document.
* Both men and women of all races and ethnic groups are eligible for this trial.

Exclusion Criteria

* Patients who have not recovered from adverse events of previous therapies.
* Patients receiving other investigational agents.
* Patients with leptomeningeal involvement.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.
* Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition or HIV-positive patients on combination antiretroviral therapy. However, HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because these patients are at increased risk of lethal infections when treated with marrow- suppressive therapy. Excluding patients on HAART is necessary due to the potential for pharmacokinetic interactions with temozolomide.
* Women who are pregnant or breast feeding, due to possible adverse effects on the developing fetus or infant due to study drug.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No